SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in four upcoming investor conferences. Canaccord Genuity – CG Horizons in Oncology Virtual…Read More
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences MarketScreener
